SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

RXII RSS Feed
Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator: Inoviorulez
Search This Board:
Last Post: 12/5/2016 10:27:27 AM - Followers: 132 - Board type: Free - Posts Today: 2

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.
 

 



RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.
 

 



This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...

NEWS

June 9, 2015 RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform

http://finance.yahoo.com/news/rxi-pharmaceuticals-strengthens-intellectual-property-110200033.html

Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-sustained-effect-120200746.html

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
 
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%
 



http://www.rxipharma.com/

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RXII
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#3640  Sticky Note Rxi Pharmaceuticals (RXII) Research Report 2016 Inoviorulez 06/19/16 09:15:20 AM
#4162   The timing of the MirImmune acquisition sure does The Other Guy 12/05/16 10:27:27 AM
#4161   You are right, RXi did not do public BioPharma 12/05/16 10:15:52 AM
#4160   hypothetically speaking, let's say they did know the sidslids 12/04/16 06:51:49 PM
#4159   biopharma. i saw that. i did sidslids 12/04/16 04:04:04 PM
#4158   i saw that. sidslids 12/04/16 03:38:26 PM
#4157   Thanks. Someone posted in Stocktwits that ladengurg will BioPharma 12/04/16 01:10:58 PM
#4156   i wrote IR to see what days they sidslids 12/04/16 12:36:01 PM
#4155   Public offering started before RXI-109 scar results release. BioPharma 12/04/16 07:29:44 AM
#4154   apparently not. sidslids 12/02/16 04:31:30 PM
#4153   11.29.16 slide show investor presentation posted sidslids 12/02/16 07:13:39 AM
#4152   Man... the high volume continues. A Volume microchips 11/30/16 07:32:10 PM
#4151   is this a hammer on the chart? sidslids 11/30/16 05:04:20 PM
#4150   I agree. I am thinking they will probably Inoviorulez 11/29/16 07:35:27 PM
#4149   regarding the offering and those on stocktwits... sidslids 11/29/16 06:28:46 PM
#4148   question for the techies: sidslids 11/26/16 08:33:01 AM
#4147   Public offering started before RXI-109 scar results release. BioPharma 11/23/16 07:46:30 PM
#4146   Guess not. Typical RXII, just a massive pump InternetForumUser 11/23/16 09:31:46 AM
#4145   The PPS held up much better than I InternetForumUser 11/22/16 07:14:44 PM
#4144   i feel your pain. i was there. sidslids 11/22/16 04:05:30 PM
#4143   I hate this stock!!!!! I have been cinders118 11/22/16 03:11:55 PM
#4142   Are you really as utterly naive as you sabaidii2 11/22/16 11:47:17 AM
#4141   Someone who knows everything wouldn't be underwater in The Other Guy 11/22/16 11:15:15 AM
#4140   If I don't own shares, why would I sabaidii2 11/22/16 10:49:27 AM
#4139   I just don't think you own shares of RXII. The Other Guy 11/22/16 10:40:17 AM
#4138   You dislike me because I see see things sabaidii2 11/22/16 10:31:06 AM
#4137   Bounce baby bounce. jaytea 11/22/16 10:09:35 AM
#4136   Looks like the rise in PPS was a InternetForumUser 11/22/16 09:03:45 AM
#4135   " an exclusive option to acquire MirImmune Inc." > crudeoil24 11/22/16 08:37:25 AM
#4134   Yes, you did well since coming on board The Other Guy 11/22/16 07:50:33 AM
#4133   But also keep in mind there was a anderbest18 11/22/16 07:10:59 AM
#4132   when was the last time this cracked a sidslids 11/22/16 03:04:50 AM
#4130   Nice to hear something other than irrational exuberance sabaidii2 11/21/16 10:45:55 PM
#4129   I agree, $16 million market cap is peanuts. The Other Guy 11/21/16 08:26:16 PM
#4128   heck, I still need $5.20 to get back shotgun 11/21/16 07:58:40 PM
#4127   Even with the 60% gain today that gives Inoviorulez 11/21/16 06:22:57 PM
#4126   * * $RXII Video Chart 11-21-16 * * ClayTrader 11/21/16 04:43:42 PM
#4125   This thing could easily run back to the jaytea 11/21/16 04:40:47 PM
#4124   weeeeeeeee! now show me some current news! sidslids 11/21/16 04:00:36 PM
#4123   There is news. Read! crudeoil24 11/21/16 03:47:04 PM
#4122   internetforumuser--i don't care what it is. this is awesome! sidslids 11/21/16 03:38:23 PM
#4121   Good luck to everyone. =D Moto260 11/21/16 03:36:07 PM
#4120   Yup no doubt about it. That pop Moto260 11/21/16 03:29:00 PM
#4119   Shorts are intimidated by super low float stocks. crudeoil24 11/21/16 03:27:55 PM
#4118   Overbought. 80 on the RSI... Looks like a Moto260 11/21/16 12:56:14 PM
#4117   If you look at the long-term chart, and microchips 11/21/16 11:28:13 AM
#4116   RXII is sitting at about $15 million market The Other Guy 11/21/16 11:07:31 AM
#4115   Obviously shares are getting churned multiple times. Would The Other Guy 11/21/16 10:45:31 AM
#4114   At 5 Million Shares Traded now. that is InternetForumUser 11/21/16 10:36:40 AM
#4113   Could a potential acquirer be buying as much Titan V 11/21/16 10:29:26 AM
#4112   Must be accumulating quite a bit. The shares The Other Guy 11/21/16 10:27:19 AM
PostSubject